Celldex Therapeutics, Inc vs. Myriad Genetics Inc
Celldex Therapeutics, Inc (CLDX) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| CLDX | MYGN | |
|---|---|---|
| Market Cap | $3.02 billion | $305.12 million |
| Revenue (TTM) | — | $806.60 million |
| Net Income (TTM) | — | $-112,600,000 |
CLDX leads on 1 of 1 size & scale factors.
Valuation
| CLDX | MYGN | |
|---|---|---|
| Price / Book | — | 1.00 |
| Price / Sales | — | 0.38 |
CLDX and MYGN split the valuation factors evenly.
Profitability
| CLDX | MYGN | |
|---|---|---|
| Net Margin | — | -13.96% |
| Return on Equity | — | -37.05% |
CLDX and MYGN split the profitability factors evenly.
Risk & Sentiment
| CLDX | MYGN | |
|---|---|---|
| Short Interest | 9.28% | 13.76% |
CLDX leads on 1 of 1 risk & sentiment factors.
Dig deeper: CLDX overview, CLDX financials, MYGN overview, MYGN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.